TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22151836
Drug: Bedtime neutral
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime neutral protamine Hagedorn (NPH) insulin
Study: 11594440
Drug: Citicoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1 g/day)
Study: 3195780
Drug: Change of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of flush solution and pressure monitoring tubing every 24 hours
Study: 3195780
Drug: Change of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of flush solution every 24 hours and change of pressure monitoring tubing every 48 hours
Study: 3195780
Drug: Change of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change of flush solution and pressure monitoring tubing every 48 hours
Study: 30007054
Drug: Flurbiprofen spray
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen spray
Study: 25953073
Drug: Fosphenytoin (FOS)
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin (FOS) 15 mg/kg phenytoin equivalent (PE) administered intravenously
Study: 25953073
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (PBO) administered intravenously
Study: 21586792
Drug: Thin catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin catheter for hysterosalpingography (HSG) during dye injection
Study: 21586792
Drug: Standard metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard metal cannula for hysterosalpingography (HSG) during dye injection
Study: 10360765
Drug: ABT-431 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-431 (5, 10, 20, 30, and 40 mg)
Study: 7585759
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg diltiazem
Study: 7585759
Drug: Titrated diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated diltiazem (200, 300, or 400 mg)
Study: 2037708
Drug: theophylline 200
Normalized name: theophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: theophylline 200 mg every 12 hours alone
Study: 2037708
Drug: theophylline 200
Normalized name: theophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: theophylline 200 mg every 12 hours with mexiletine 150 mg every 8 hours
Study: 6166800
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg thrice daily
Study: 26176605
Drug: Selective low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selective low-dose spinal anesthesia
Study: 19168521
Drug: Continuous aortic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous aortic flow augmentation device
Study: 19168521
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone analogue
Study: 15326018
Drug: Survey of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey of internal medicine residents
Study: 11430963
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg per day
Study: 3623678
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg p.o.
Study: 25527456
Drug: Single 2-L
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-L dose of Moviprep
Study: 25527456
Drug: Two separate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two separate doses of 1 L of Moviprep
Study: 21855837
Drug: Prolonged bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged bivalirudin infusion (4-hour infusion after PCI)
Study: 21855837
Drug: Standard bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bivalirudin infusion (peri-PCI infusion)
Study: 22162175
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus abciximab
Study: 19247742
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (10 ml 0.5% - 50 mg)
Study: 19247742
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (10 ml 0.25% - 25 mg)
Study: 19247742
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (40 ml 0.0625% - 25 mg)
Study: 15229391
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus tirofiban (n = 50)
Study: 3377459
Drug: Carumonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carumonam (1 g every 8 h)
Study: 3377459
Drug: Gentamicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1 mg/kg every 8 h)
Study: 19117887
Drug: Laronidase (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laronidase (recombinant human alpha-l-iduronidase)
Study: 16937109
Drug: Profylin fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profylin fluoride gel with buffering components (active gel)
Study: 16937109
Drug: Profylin fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profylin fluoride gel without buffering components (placebo gel)
Study: 9118789
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ofloxacin and 500 mg metronidazole intravenously, twice daily
Study: 9118789
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no initial antibiotics), n = 13
Study: 8335858
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of Beconase AQ nasal spray (400 micrograms daily)
Study: 8335858
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required (prn) use of Beconase AQ nasal spray
Study: 19070383
Drug: ARB (losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (losartan 25‐50mg/day, candesartan 4‐8 mg/day, valsartan 40‐80 mg/day, telmisartan 20‐40 mg/day)
Study: 14757258
Drug: Antiarrhythmic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic Therapy
Study: 2129071
Drug: High-dose glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glycyrrhizin (Stronger Neo-Minophagen C, SNMC) administered intravenously daily for the first 3 weeks, and every second day for the following 8 weeks. Dosage: 100-200 ml in 21 patients and 400-800 ml in the other 21.
Study: 7380749
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention and methylphenidate (0.25 mg/kg)
Study: 7380749
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention and methylphenidate (0.75 mg/kg)
Study: 7380749
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of methylphenidate after 13 weeks of behavioral intervention
Study: 7380749
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of methylphenidate after 13 weeks of behavioral intervention
Study: 7380749
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication after 13 weeks of behavioral intervention
Study: 31410968
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Study: 31854112
Drug: Standard 12-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 12-month DAPT followed by 12-month aspirin monotherapy
Study: 31410968
Drug: 1-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Study: 25081735
Drug: Isotretinoin with
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin with additional antihistamine (desloratadine)
Study: 2479083
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of pancreatic enzyme substitution (Pancrease)
Study: 2479083
Drug: Regular dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dosage of pancreatic enzyme substitution (Pancrease)
Study: 1096685
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of naphazoline hydrochloride and antazoline phosphate
Study: 31536941
Drug: Non-severe hypoglycaemic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-severe hypoglycaemic clamp (plasma glucose: 3.1 ± 0.3 mmol/L)
Study: 31536941
Drug: Normoglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycaemic clamp (plasma glucose: 5.8 ± 0.3 mmol/L)
Study: 26403986
Drug: Oral arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral arsenic (Realgar‐Indigo naturalis formula, RIF) plus all‐trans retinoic acid (ATRA)
Study: 26403986
Drug: Oral arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral arsenic (RIF) during maintenance treatment
Study: 26403986
Drug: Intravenous arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous arsenic trioxide (ATO) during maintenance treatment
Study: 23999661
Drug: 1.1 g
Normalized name: Giazo 1.1 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 g of n‐3 PUFA daily for six weeks
Study: 23999661
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of olive oil daily for six weeks
Study: 18998188
Drug: Phytosterol-enriched yogurt
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-enriched yogurt (1.6 g esterified phytosterols, equivalent to 1.0 g free phytosterol)
Study: 16452747
Drug: Weekly dry
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly dry dressing changes without pin-site care
Study: 16452747
Drug: Daily pin-site
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pin-site care with a solution of one-half normal saline solution and one-half hydrogen peroxide
Study: 16452747
Drug: Chlorhexidine-impregnated discs
Normalized name: DISC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-impregnated discs (Biopatch) with weekly changes
Study: 8929232
Drug: Bunazosin retard
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin retard (6 mg)
Study: 17304143
Drug: Azathioprine (2.0-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.0-2.5 mg/kg per day)
Study: 8878220
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin A therapy
Study: 6366346
Drug: 1% aqueous
Normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aqueous solution of indomethacin
Study: 17599420
Drug: Fibrate and
Normalized name: Fenofibrate and rosuvastatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrate and statin therapy for lipid management
Study: 15691617
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg for 4 weeks
Study: 15691617
Drug: Bendroflumetazide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumetazide 2.5 mg for 4 weeks
Study: 9794277
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) - 12 weekly sessions of individual CT
Study: 8560527
Drug: Dextrose 2
Normalized name: Dextrose 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 2 mg/kg/min infused over 60 min with heparin and Intralipid (group C)
Study: 8560527
Drug: Dextrose 2
Normalized name: Dextrose 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 2 mg/kg/min infused over 60 min alone (group A)
Study: 8560527
Drug: Dextrose 4
Normalized name: DEXTROSE 40% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 4 mg/kg/min alone (group B)
Study: 8560527
Drug: Dextrose 4
Normalized name: DEXTROSE 40% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 4 mg/kg/min with heparin and Intralipid (group D)
Study: 2155688
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2.6 mg active drug per nostril, q.i.d.)
Study: 25308868
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride 10 mg
Study: 25308868
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride 25 mg
Study: 23570280
Drug: Compounded morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded morphine
Study: 19351732
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol and progesterone for 7 days
Study: 11522495
Drug: HDV-insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDV-insulin (0.1 U/kg)
Study: 11522495
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (0.1 U/kg)
Study: 11522495
Drug: HDV-insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HDV-insulin
Study: 3302342
Drug: Ampicillin suppository
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin suppository (4 x 125 mg)
Study: 3302342
Drug: Oral form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral form of ampicillin (4 x 125 mg)
Study: 22957521
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (insulin-dosing algorithm targeting blood glucose level of 80 to 110 mg/dL)
Study: 17666497
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone (25 mg or 50 mg every 14 days)
Study: 17666497
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (5-20 mg/day)
Study: 15502112
Drug: Budesonide/formoterol (bud/form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (bud/form) maintenance + relief (80/4.5 microg twice a day with 80/4.5 microg as-needed)
Study: 15502112
Drug: Budesonide/formoterol (bud/form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (bud/form) + SABA (terbutaline 0.4 mg)
Study: 15502112
Drug: Budesonide (bud)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (bud) + SABA (terbutaline 0.4 mg)
Study: 9585655
Drug: Amitriptyline (AMI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (AMI), flexible dose, final dose 173.1 mg/day ± 56.3 mg/day
Study: 779502
Drug: Clofazimine 200
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine 200 mg daily 6 days per week (regimen 1)
Study: 779502
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg three times weekly (regimen 2)
Study: 779502
Drug: Clofazimine 300
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine 300 mg weekly (regimen 3)
Study: 779502
Drug: Clofazimine 600
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine 600 mg every other week (regimen 4)
Study: 779502
Drug: Clofazimine 600
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine 600 mg on 2 consecutive days every 4 weeks (regimen 5)
Study: 779502
Drug: Clofazimine 200
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine 200 mg daily 6 days per week (regimen 6)
Study: 779502
Drug: Dapsone, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone, starting with a small dosage and increasing to 100 mg daily 6 days per week (regimen 7)
Study: 29744804
Drug: Controlled antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled antipsychotic treatment for 12 weeks
Study: 30376810
Drug: Programmed Intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed Intermittent Epidural Bolus (PIEB) 6 mL/h of ropivacaine 0.2%
Study: 30376810
Drug: Continuous Epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Epidural Infusion (CEI) 6 mL/h of ropivacaine 0.2%
Study: 26772985
Drug: Early prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early prophylactic levothyroxine (LT4) treatment
Study: 22095403
Drug: Manual (non-US-guided)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual (non-US-guided) injection
Study: 22095403
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of US-guided vs Manual injection
Study: 16252739
Drug: Injection pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pressure of 30 s/mL
Study: 16252739
Drug: Injection pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pressure of 160 s/mL
Study: 12014163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no solution applied)
Study: 31769596
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel treatment
Study: 31134827
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) in addition to conventional treatment, 5 days per week, 60 min each, 100% oxygen at 2 standard atmospheric pressures for 12 weeks.
Study: 31134827
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Control group).
Study: 28186838
Drug: Group <70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group <70 (mean dose <70.2Gy)
Study: 28186838
Drug: Group >70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group >70 (mean dose >70.2Gy)
Study: 26404912
Drug: Tiotropium 1.25
Normalized name: TIOTROPIUM 1.25MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 1.25 µg + Olodaterol 5 µg
Study: 26404912
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 µg + Olodaterol 5 µg
Study: 26404912
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 µg + Olodaterol 5 µg
Study: 26404912
Drug: Tiotropium 1.25
Normalized name: TIOTROPIUM 1.25MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 1.25 µg + Olodaterol 10 µg
Study: 26404912
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 µg + Olodaterol 10 µg
Study: 26404912
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 µg + Olodaterol 10 µg
Study: 21495198
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of hyoscine-N-butyl bromide (HBB) rectal suppository
Study: 19054777
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone application preceding standard gonadotrophin ovarian stimulation
Study: 19054777
Drug: High-dose gonadotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gonadotrophin with minidose GnRH agonist protocol
Study: 19054777
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone application
Study: 19054777
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone application (normal basal FSH levels)
Study: 19054777
Drug: High-dose gonadotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gonadotrophin with minidose GnRH agonist protocol (normal basal FSH levels)
Study: 17613264
Drug: NO-collecting solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO-collecting solutions with NO-scavenging compounds (hemoglobin or 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide) placed inside tubing attached to skin for 20 min
Study: 15598977
Drug: IM862 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM862 (5 mg intranasally every other day)
Study: 9617985
Drug: Naltrexone 200
Normalized name: NALTREXONE 200 mg / TRIAMCINOLONE 6.5 mg SUBCUTANEOUS IMPLANT [Naltrexone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 200 mg/day for 3 weeks
Study: 9617985
Drug: Naltrexone (subsequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (subsequent treatment)
Study: 7925218
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 for intubation followed by an infusion controlled by closed‐loop feedback at 90% block.
Study: 2701811
Drug: Inappropriate sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate sequential analysis
Study: 772669
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pseudoephedrine and triprolidine
Study: 31229641
Drug: r-ATG (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-ATG (4.5 mg/kg)
Study: 28965280
Drug: Acetazolamide (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (oral, once daily, dose-adjusted to body weight)
Study: 19565156
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy agents + isometric and stretching exercises